Analytical Data
-
Gene name
SLC1A1
- Application
-
Alternative Names
Excitatory amino-acid carrier 1 Neuronal and epithelial glutamate transporter Sodium-dependent glutamate/aspartate transporter 3 Solute carrier family 1 member 1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43005
-
Expression Region
430-524aa
-
Molecular Weight
37.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC1A1, a member of the solute carrier family 1, encodes a high-affinity sodium-dependent glutamate transporter primarily expressed in the central nervous system. This protein plays a crucial role in maintaining glutamate homeostasis, which is essential for normal neurotransmission and preventing excitotoxicity. Dysregulation of SLC1A1 has been implicated in various neurological disorders, including epilepsy and schizophrenia, making it a target of interest for therapeutic interventions. Research on SLC1A1 recombinant proteins has advanced significantly, allowing scientists to study its functional properties, interaction with ligands, and the impact of specific mutations associated with disease. These studies often involve the expression of SLC1A1 in heterologous systems, such as yeast or mammalian cells, to produce sufficient quantities of the protein for structural and functional analysis. Understanding the mechanism of SLC1A1 will not only provide insights into its physiological roles but also aid in the development of novel drugs that can modulate its activity in pathological conditions. Further exploration of this transporter could lead to improved strategies for managing glutamate-related disorders, emphasizing the importance of SLC1A1 within the field of neurobiology.
